NeuroHealing Pharmaceuticals is a clinical-stage company developing therapies to improve the neuro-rehabilitation process and functional outcome for patients who have suffered debilitating injuries to the central nervous system.

NeuroHealing is working in a long neglected area, the needs of post-acute and chronic neuro-rehabilitation patients. Major chronic neuro-rehabilitation patients include victims of traumatic brain injury and stroke, patients with neurodegenerative diseases such as Parkinson’s, ALS and MS, and other motor neuron conditions.

By discovering new uses of known drugs, reformulating and designing drug delivery modes best suited for this patient population, NeuroHealing believes it can rapidly bring needed products to this market. NeuroHealing currently has in development three drug candidates, all with preliminary evidence of clinical benefit: NH001 to accelerate the emergence of patients from a coma, NH004 to treat the social debilitating condition of sialorrhea (excessive salivation) and NH02D to help in the rehabilitation of motor recovery of stroke and traumatic brain injury patients living with their disabilities.

Guided by a strong and experienced management team, NeuroHealing plans to become the leading pharmaceutical company addressing the needs of the under-served neuro-rehabilitation patients, who currently face rehab costs exceeding $35 billion annually.